Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)

NCT03224819 · clinicaltrials.gov ↗
EARLY_PHASE1
Phase
TERMINATED
Status
46
Enrollment
INDUSTRY
Sponsor class

Stopped Priortization of other Programs

Conditions

Interventions

Sponsor

Amgen